Shares of Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) fell 13.2% on Thursday . The stock traded as low as $11.00 and last traded at $10.0580. Approximately 39,557 shares changed hands during mid-day trading, a decline of 10% from the average daily volume of 43,944 shares. The stock had previously closed at $11.59.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded shares of Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, May 14th. One analyst has rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold”.
Check Out Our Latest Research Report on NNNN
Anbio Biotechnology Stock Down 0.1%
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Featured Articles
- Five stocks we like better than Anbio Biotechnology
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
- Tesla: After a Rough Quarter, 2 Very Different Futures Come Into Focus
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
